HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Advances Pacira’s “5x30” path to becoming an innovative biopharmaceutical organization ---- Adds novel, high-capacity, local-delivery platform ...

European equities traded in the US as American depositary receipts kicked off the week on strong note late Monday morning, surging 1.83% higher to 1,442.61 on the S&P Europe Select ADR Index. From ...

New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned ...

Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.

LUMRYZ™ generated $50.4 million in sales in the fourth quarter, up 158% year-over-year, taking the full-year total to $169.1 million, in line ...

The biopharmaceutical industry showed a mixed performance in 2024, with the aggregate market capitalisation of the top 20 biopharmaceutical firms increasing by 1.7% to $3.7t as of 31 December.

The global microbiology culture market propelled by increasing demand across sectors such as pharmaceuticals, food and ...

(NASDAQ:SVA) ("SINOVAC" or the "Company"), a leading provider of biopharmaceutical products in China, today announced that SINOVAC has received on February 8, 2025 a formal court order (the “Order”) ...

LB Pharmaceuticals CEO Heather Turner explains why 18 years as a general counsel provided her with an advantageous ...